Small Molecules For Fighting Cancer

  • ChemPubSoc Europe Logo
  • DOI: 10.1002/chemv.201000004
  • Author: David Bradley
  • Published Date: 12 May 2010
  • Source / Publisher: Angewandte Chemie International Edition/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
thumbnail image: Small Molecules For Fighting Cancer

The malfunctioning of tumor necrosis factor (TNF-alpha, TNF-a) has been linked to tumor growth, diabetes, and auto-inflammatory diseases such as rheumatoid arthritis and Crohn’s disease. Finding small molecules that can control its behavior could lead to the development of novel products for a wide range of health problems including cancer.

Identify Potent Inhibitors of TNF-a

A team led by Dik-Lung Ma of the Hong Kong Baptist University and Chung-Hang Leung of The University of Hong Kong, and co-workers from the University of California, San Diego, and The Scripps Research Institute, La Jolla, have used virtual screening to identify potent inhibitors of TNF-a.

Currently, TNF-a is targeted by synthetic antibodies, such as etanercept and infliximab. These are approved for treating inflammatory diseases but cause side-effects by weakening the immune system, leading to opportunistic infections. However, identifying small molecules to replace these treatments has proved difficult, with just two emerging previously: a polysulfonated naphthylurea suramin and an indole-linked chromone (SPD304), neither of which is without problems such as low potency, poor selectivity, and side-effects.

Identify New Leads

To identify new leads, the team used the reported co-crystal structure of TNF-a with SPD304. This compound fits the protein’s binding pocket well, so screening for compounds with a similar profile but without its toxic moiety could offer up useful candidates.

The researchers screened 20 000 compounds from a natural product type library and investigated further the 16 most promising. Two leads emerged. One a pyrazole-linked quinuclidine and the other an indolo-[2,3-a]quinolizidine. These two compounds can directly target human TNF-a and are at least as potent as previous compounds. The indoloquinolizidine has an IC50 (half maximal inhibitory concentration) of 10 micromolar and the quinuclidine 5 micromolar compared the lower IC50 of 3 micromolar for SPD304 itself.

Hit-to-Lead Optimization

“We are currently pursuing hit-to-lead optimization using a combination of computational, analytical and synthetic techniques to generate more potent anti-TNF analogues for in vitro testing,” team member Daniel Chan told ChemistryViews. “Once more potent inhibitors of TNF-a have been identified using our enzyme and cellular assays, the next step will involve in vivo animal studies to confirm the safety and efficacy of the drugs.”

The team expects their two compounds to be much less toxic than the first two TNF-a inhibitors. The researchers are currently using a computer-based hit-to-lead optimization technique to produce additional analogues for in vitro testing.

There Remains a Lot More Work To Do – F. Driss, University of Paris

Fathi Driss of University of Paris, France, agrees that finding small molecules for modulating the activity of TNF-a could help avoid the immunological side-effects seen with antibody therapies. “Only small molecules would exhibit some efficacy to modulate the harmful effects of TNF-a without a wide range of side effects,” he explains. Screening likely candidates is one approach, but Driss believes that a lot more effort will be required before a product based on small molecule chemistry becomes available. “My feeling is that there remains a lot more work to do,” he says, “I also have some concerns about bioavailability and metabolic pathways that may lead to unidentified metabolites.”

The Driss team is pursuing naturally occurring compounds for controlling TNF-a via a different route in which extracts of common dietary substances are tested. Recently, he and his team reported positive data on punicic acid from pomegranate seed oil.


Article Views: 4743

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from, please contact us first for permission. more

CONNECT: on Facebook on Twitter on YouTube on LinkedIn Sign up for our free newsletter

A product of ChemPubSoc Europe (16 European Chemical Societies)published by Wiley-VCH